Drug- and medtech developer Windtree Therapeutics (NSDQ:WINT) today announced it named John Hamill as SVP and chief financial officer, replacing John Tattory, who is leaving to pursue other opportunities.
Hamill joins the company, which develops drug product and devices to treat acute cardiovascular and pulmonary disease, with 30 years in the pharma, biopharma and clinical research industries.
“We are delighted to have John join the Windtree team. He brings to us broad industry experience, having served as a seasoned financial executive and in a variety of senior roles for publicly traded companies,” said Windtree CEO Craig Fraser in a news release.
Most recently, he consulted for several life sciences companies including Trevana Inc., where he led a recent financing. He also saw Savient Pharmaceticals and PharmaNet through their own acquisitions, which brought in close to $400 million.
“I am very pleased to join Windtree, with its multiple late-stage assets and programs that aim to address unmet needs in significant cardiovascular and respiratory markets,” Hamill said. “ It’s an exciting time for the company and I look forward to being part of a talented team focused on building value.”
Hamill received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.
In May, Windtree raised over $20 million through a public offering of 2.76 million units at $7.25 per unit and the full exercise of the underwriters’ option to purchase 413,793 additional shares of common stock and 413,793 additional warrants. In connection with the offering, the company’s common stock began trading on NASDAQ under the symbol WINT.